# Progress Note 02 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Zora Neale Hurston (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML040-SYN-TD
- Date: 1958-03-23
- Fictional facility: St. Posthumous Health Center
- Fictional author: Lorraine Abernathy-Osei, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Two-week review: blood pressure, echocardiogram and cardiology consultation. **S**

## History of present illness

Ms. Hurston returns two weeks after intake and is seen the same day by Dr. Okafor-Whitfield of cardiology after her echocardiogram this morning. The 24-hour ambulatory recording before her first doses averaged 158/96 mmHg (daytime 163/99, night 149/90), with no fall in pressure at night, which confirms stage 2 hypertension. She started chlorthalidone 12.5 mg and amlodipine 5 mg the next morning; her home readings over the past week average 146/88. The morning headaches have gone. She is still breathless on one flight of stairs and her ankles swell a little by evening. She has had no lightheadedness, cramps or palpitations. The echocardiogram shows a preserved ejection fraction with thick heart walls and stiff filling. She met the community health worker last week: her SNAP application is in, and a SHINE counselor will see her on Thursday about drug coverage. **S**

| Element | Detail |
|---|---|
| Ambulatory blood pressure | 24-hour mean 158/96 mmHg; daytime 163/99; night 149/90 (non-dipping) |
| Home blood pressure on treatment | Average 146/88 mmHg over seven days |
| Symptoms | Headaches gone; breathless on one flight of stairs; mild evening ankle swelling |
| Echocardiogram | Ejection fraction 62%; concentric left ventricular hypertrophy; grade II diastolic dysfunction |
| KCCQ-12 | 54 |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Cardiovascular | Positive | Breathless on one flight of stairs; mild evening ankle swelling; no chest pain, palpitations, orthopnea or night breathlessness |
| Neurological | Negative | Headaches resolved; no weakness, numbness, speech or vision change |
| Genitourinary | Negative | Passing more urine in the mornings; no burning |
| Musculoskeletal | Negative | No cramps |

4 systems reviewed. **S**

## Current medications

- Amlodipine 5 mg oral tablet, one tablet every morning **S**
- Chlorthalidone 25 mg oral tablet, one-half tablet (12.5 mg) every morning **S**
- Dapagliflozin 10 mg oral tablet, one tablet daily; pause on days of vomiting, diarrhea or not eating or drinking **S**
- Atorvastatin 20 mg oral tablet, one tablet daily **S**

## Allergies

- No known allergy **S**

## Objective

BP 150/90 mmHg; pulse 78 bpm; respirations 16/min; temperature 36.6 °C; oxygen saturation 97% on room air; weight 83.4 kg; BMI 30.6 kg/m². All vital signs are synthetic.

Sodium: 138 mmol/L; Potassium: 3.6 mmol/L; Creatinine: 0.94 mg/dL; eGFR (CKD-EPI 1953): 67 mL/min/1.73 m²; Glucose: 98 mg/dL; Magnesium: 1.9 mg/dL; LVEF by echocardiogram: 62%; Left atrial volume index: 38 mL/m² (high); Mitral E/e' ratio (average): 15 (high); KCCQ-12 overall summary: 54. All results are synthetic.

## Change since baseline

- Sodium: 140 mmol/L at baseline, 138 mmol/L at this visit **S**
- Potassium: 3.9 mmol/L at baseline, 3.6 mmol/L at this visit **S**
- Creatinine: 0.88 mg/dL at baseline, 0.94 mg/dL at this visit **S**
- eGFR (CKD-EPI 1953): 72 mL/min/1.73 m² at baseline, 67 mL/min/1.73 m² at this visit **S**
- Glucose: 96 mg/dL at baseline, 98 mg/dL at this visit **S**
- Magnesium: 2 mg/dL at baseline, 1.9 mg/dL at this visit **S**

## Immunizations given today

- Pneumococcal conjugate vaccine PCV20 **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; blood pressure 150/90, pulse 78; weight 83.4 kg, down 0.8 kg |
| Neck | Jugular venous pressure not raised; no carotid bruits |
| Cardiovascular | Regular rhythm; sustained apical impulse; S4; no murmur |
| Respiratory | Clear |
| Extremities | Trace ankle edema |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Hypertensive heart disease with heart failure** (I11.0). Stage 2 hypertension confirmed by ambulatory monitoring, with concentric left ventricular hypertrophy on ECG and echocardiogram. Home average 146/88 after one week on the two-drug combination: improving, not yet at the target below 130/80. Dr. Okafor-Whitfield agrees with the combination and the diagnosis. **S**
   - Continue chlorthalidone 12.5 mg and amlodipine 5 mg.
   - Atorvastatin 20 mg daily for primary prevention, with a lipid panel at four to twelve weeks.
   - Home readings twice daily for the week before each visit.
2. **Heart failure with preserved ejection fraction, NYHA class II** (I50.32). Breathlessness, raised NT-proBNP (480 pg/mL), an enlarged left atrium, an E/e' of 15 and concentric hypertrophy with an ejection fraction of 62% establish HFpEF from hypertensive heart disease. Cardiology found no red flags for amyloidosis, valve disease or ischemia. **S**
   - Dapagliflozin 10 mg daily, with sick-day rules; supplied through the manufacturer's patient assistance program until drug coverage begins.
   - Daily weights with a written plan; call for a gain of more than 1 kg in a day or 2 kg in a week.
   - Metabolic panel in two weeks.
   - Pneumococcal vaccine (PCV20) today.
3. **Low income without drug coverage** (Z59.6). Generic medicines in 90-day fills cost her little; dapagliflozin has no low-cost generic on her pharmacy's list. **S**
   - SHINE counselor this week for Extra Help and the Medicare Savings Program.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Blood pressure in the clinic (seated, average of two readings, large cuff) | Every visit | Completed today | 150/90 mmHg |
| Examination | Out-of-office blood pressure (ambulatory at diagnosis; home readings when treatment changes) | At diagnosis and with each treatment change | Completed today | Ambulatory 24-hour mean 158/96 (non-dipping) before treatment; home average 146/88 on treatment |
| Examination | Weight, volume status (jugular venous pressure, edema, lungs) and NYHA class | Every visit | Completed today | 83.4 kg; jugular venous pressure not raised; trace ankle edema; lungs clear; NYHA II |
| Laboratory | Metabolic panel (sodium, potassium, creatinine and eGFR) and magnesium | One to two weeks after starting or changing a diuretic, SGLT2 inhibitor or MRA; then every three to six months | Completed today | Two weeks after chlorthalidone: sodium 138, potassium 3.6, creatinine 0.94 mg/dL (eGFR 67), magnesium 1.9 |
| Imaging | ECG and echocardiogram | At diagnosis; repeat only with unexplained clinical change | Completed today | ECG at intake: left ventricular hypertrophy, sinus rhythm. Echocardiogram today: ejection fraction 62%, left atrial volume index 38 mL/m2, E/e' 15, concentric hypertrophy |
| Survey | KCCQ-12 heart failure health status | At diagnosis, then every three to six months | Completed today | 54 at diagnosis |
| Laboratory | Lipid panel | Four to twelve weeks after starting a statin; then yearly | Ordered | LDL 132 mg/dL at intake; atorvastatin started today; panel due in four to twelve weeks |
| Laboratory | Urine albumin-to-creatinine ratio | Yearly | Up to date | 22 mg/g at intake |
| Laboratory | Hemoglobin A1c | Yearly | Up to date | 5.6% at intake |
| Survey | Depression screen (PHQ-2, then PHQ-9 if positive) | Yearly | Up to date | PHQ-2 1 at intake |
| Examination | Eye examination for hypertensive retinopathy | Yearly | Up to date | Arteriolar narrowing and nicking without hemorrhage at intake; dilated examination to be arranged |
| Self-management | Self-care: daily weights, less salt, sick-day rules and the BE FAST stroke signs | Every visit | Completed today | Scale at home; written weight plan; sick-day rules for dapagliflozin; BE FAST card reviewed |
| Medication safety | Medicine costs and coverage (generics, 90-day fills, patient assistance, Extra Help, Medicare Savings Program) | Every visit | Completed today | Generics in 90-day fills; patient assistance for dapagliflozin; SHINE appointment this week |
| Self-management | Food access | Every visit | Completed today | SNAP application submitted with the community health worker |
| Referral | Cardiology consultation | At diagnosis | Completed today | Seen by Dr. Okafor-Whitfield today |

## Goal progress

- Blood pressure below 130/80 mmHg in the clinic and at home within six months. In progress; target 1958-06-01. **S**
- Breathlessness only on heavy exertion and a KCCQ-12 score at least 15 points higher within six months. In progress; target 1958-10-19. **S**
- Every medicine affordable: generic 90-day fills, patient assistance until drug coverage begins, Extra Help and the Medicare Savings Program. In progress; target 1958-06-01. **S**
- Enough food through the month. In progress; target 1958-06-01. **S**
- Know the BE FAST signs of stroke and call 911 at once if any appear. In progress; target 1958-04-06. **S**

## Medication changes

- Started: Dapagliflozin 10 mg oral tablet, one tablet daily; pause on days of vomiting, diarrhea or not eating or drinking **S**
- Started: Atorvastatin 20 mg oral tablet, one tablet daily **S**

## Guideline basis

- 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults (2025), American Heart Association and American College of Cardiology (Circulation 2025;152(11):e114-e218)
- 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure (2022), American Heart Association, American College of Cardiology, and Heart Failure Society of America (Circulation 2022;145(18):e895-e1032)
- 2023 ACC Expert Consensus Decision Pathway on Management of Heart Failure With Preserved Ejection Fraction (2023), American College of Cardiology (J Am Coll Cardiol 2023;81(18):1835-1878)
- CMID: Clinical Monitoring Intelligence Database, hypertension and heart failure monographs (2026), Aether Forge
- Signs and Symptoms of Stroke (2026), Centers for Disease Control and Prevention
- Help with drug costs (Extra Help) (2026), Centers for Medicare & Medicaid Services (Medicare.gov)
- SHINE (Serving Health Insurance Needs of Elders), Florida's State Health Insurance Assistance Program (2026), Florida Department of Elder Affairs

## Follow-up

- Two-week review with a metabolic panel. Call for lightheadedness, a weight gain beyond the plan, or breathlessness at rest; call 911 for any BE FAST sign or chest pain. **S**
- Next scheduled visit 1958-04-06: two-week review after dapagliflozin: metabolic panel, blood pressure and potassium, and benefits applications. **S**
